MA
TMBR

MCF Advisors’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

MCF Advisors’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7
Closed -$24K – 507
2018
Q1 		$24K Buy
+7
New +$20.8K ﹤0.01% 272

Other funds holding TMBR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

MCF Advisors's TMBR Position: Q2 2018 in Review

MCF Advisors sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q2 2018, closing a stake of 7 shares — an estimated $24K sold.

MCF Advisors first reported a position in TMBR in Q1 2018 and held it in 1 quarter. The position peaked at $24K in Q1 2018. 19 funds tracked by Wall St. Rank hold TMBR as of Q2 2018.

  • MCF Advisors reported no remaining Timber Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • MCF Advisors sold 7 Timber Pharmaceuticals, Inc. shares in Q2 2018, an estimated $24K.
  • MCF Advisors first reported a position in Timber Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • MCF Advisors's Timber Pharmaceuticals, Inc. position peaked at $24K in Q1 2018.
  • 19 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q2 2018.

Based on MCF Advisors's 13F filing for Q2 2018, filed 20 Jul 2018.